Axsome Therapeutics Inc

Graduate Research Intern - Machine Learning for Protein Structure Prediction

United States

Not SpecifiedCompensation
InternshipExperience Level
Part TimeJob Type
UnknownVisa
Biotechnology, Pharmaceuticals, Computational BiologyIndustries

Position Overview

  • Location Type: Remote
  • Job Type: Part-Time
  • Salary: Not specified
  • Internship Duration: Fall 2025
  • Brief Description: Iambic Therapeutics is seeking a graduate student for a research internship to contribute to the development of NeuralPLexer, a protein structure prediction platform. This internship focuses on cutting-edge machine learning approaches for structural biology, particularly understanding protein conformational dynamics and affinity. It’s a collaborative opportunity to develop next-generation methods combining deep learning with physics-based approaches.

Requirements

  • Education:
    • Currently enrolled in a PhD program in Computational Chemistry, Computational Biophysics, Computer Science, Computational Biology, or related field.
  • Skills:
    • Proficiency in Python
    • Experience with enhanced sampling and classical molecular dynamics simulations
    • Experience with deep learning frameworks (PyTorch preferred)
    • Understanding of protein structure and protein dynamics

Responsibilities

  • Develop and train deep learning models for protein structure prediction.
  • Work with molecular dynamics simulations and enhanced sampling techniques to validate and improve model predictions.
  • Analyze large-scale protein structural data to identify patterns in conformational changes.
  • Assist in implementing new model architectures and training strategies.
  • Contribute to the model evaluation framework, particularly for conformational accuracy.
  • Participate in team meetings and present findings to the computational group.

Learning Opportunities

  • Work with state-of-the-art protein structure prediction models.
  • Learn to integrate physical principles into machine learning approaches.
  • Gain experience with enhanced sampling methods.
  • Understand real-world applications in drug discovery.
  • Collaborate with experts in both ML and computational chemistry.

About Iambic Therapeutics

  • Founded: 2019
  • Headquarters: San Diego, California
  • Description: Iambic Therapeutics is disrupting the therapeutics landscape with its AI-driven drug-discovery platform. The company has assembled a world-class team uniting AI experts and experienced drug hunters. The Iambic platform is delivering high-quality, differentiated therapeutics to clinical stage with unprecedented speed and across multiple target classes and mechanisms of action. They are advancing an internal pipeline of clinical assets to address urgent unmet patient needs.
  • Website: iambic.ai

Mission & Core Values

  • Mission: To deliver better medicines through innovations in AI-based discovery technologies.

Skills

Python
Enhanced sampling
Molecular dynamics simulations
Deep learning frameworks
PyTorch
Protein structure
Protein dynamics

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

New York City, New YorkHeadquarters
2012Year Founded
$430.7MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees

Benefits

Performance Bonus
Company Equity

Risks

Increased competition from companies like Compass Pathways in the CNS market.
Potential delays in AXS-07 launch amid growing market anticipation.
Departure of key personnel like Lori Englebert may impact strategic direction.

Differentiation

Axsome focuses on CNS disorders with limited current treatment options.
AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.
Axsome's balanced portfolio includes both clinical and research stage products.

Upsides

FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.
Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.
Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

Land your dream remote job 3x faster with AI